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Abstract
Background: To explore to what extent synovial hypertrophy in joints without Doppler activity is a sign of active
disease, we investigated the sensitivity to change of synovial hypertrophy without Doppler activity during biological
disease-modifying antirheumatic drug (bDMARD) treatment in rheumatoid arthritis (RA) patients.
Method: RA patients initiating or switching bDMARD treatment had ultrasound (US) performed on 36 joints at
baseline, and at 3 and 6 months. Synovial hypertrophy by grayscale US and Doppler activity were graded separately
from 0 to 3 at the joint level for all time points. Changes in synovial hypertrophy in joints without Doppler activity
during treatment were assessed and compared with changes in synovial hypertrophy in joints with Doppler activity.
Results: We included 151 patients (82.8% women, 80.1% seropositive for anticyclic citrullinated peptide) with a mean
± standard deviation age of 51.4 ± 13.2 years, a disease duration of 9.9 ± 7.9 years, and baseline Disease Activity Score
28-joint count C-reactive peptide (DAS28-CRP) of 4.14 ± 1.32. At baseline, 44.8% of all joints examined (n = 5225) had
synovial hypertrophy≥ 1 and 50.7% of these had synovial hypertrophy without Doppler activity. The improvement in
synovial hypertrophy was similar in joints with and without Doppler activity but, when adjusting for the baseline score
of synovial hypertrophy, joints with synovial hypertrophy without Doppler had a higher tendency towards a decrease
than joints with synovial hypertrophy with Doppler activity independent of grade (3 months: p < 0.0001; 6 months:
p = 0.0003).
Conclusion: Joints with synovial hypertrophy without Doppler activity improve during treatment, independent of the
grade. Thus, SH without Doppler activity is not a sign of inactive disease. These findings indicate that joints
with synovial hypertrophy without Doppler activity should also be taken in to account when assessing disease
activity by US.
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Background
The treatment strategy and treatment options for rheuma-
toid arthritis (RA) have improved considerably over the
past years. The strategy is to “treat-to-target” (with a target
of remission or low disease activity (LDA)) and includes
early and aggressive treatment with mono- or combination
therapy using disease-modifying antirheumatic drugs
(DMARDs). Furthermore, rapid treatment escalation is rec-
ommended when there is insufficient clinical response, in-
cluding the addition of biological DMARDs (bDMARDs).
The aim of this strategy is to gain rapid disease control and
avoid inflammation, thereby preventing pain and joint de-
struction and improving physical function [1, 2].
In addition to conventional clinical monitoring of treat-
ment in RA patients, ultrasound (US) has been increas-
ingly applied over the last decade to assess disease activity
and the response to therapy. As US has been proven to be
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more sensitive than clinical joint evaluation [3, 4], the
addition of US to clinical joint evaluation has allowed for
a more elaborate joint involvement, helping in correctly
classifying and diagnosing RA patients [5]. When asses-
sing synovitis by US, two components are evaluated: syn-
ovial hypertrophy by grayscale (GS) US and hyperemia by
Doppler US. Scoring systems have been developed for the
two components, with each scored individually [6–10].
Most emphasis in the clinical studies/trials has been on
changes in Doppler activity as this is considered to reflect
the inflammatory activity, i.e., disease activity [10–12], and
hence the primary aim has been the elimination of signs
of Doppler activity [13–17].
Joints with synovial hypertrophy without Doppler ac-
tivity are generally believed to be inactive changes [12]
and without the ability to change when optimizing treat-
ment [18], thereby being of minimal clinical importance.
However, very little is known about how GS synovial
hypertrophy without Doppler activity behaves in joints
during treatment, i.e., if these joints have the potential to
improve. The fact that GS synovial hypertrophy per se
(though weaker than Doppler activity) is a predictor of
erosive progression in patients in remission [19, 20] sug-
gests that GS synovial hypertrophy is important and pos-
sibly should be part of imaging remission, and that
elimination of Doppler per se is potentially not the only
treatment goal in RA patients when considering treat-
ment escalation.
It is therefore of great importance to explore the revers-
ibility of synovial hypertrophy in joints without Doppler
activity as this—if sensitive to change—may impact deci-
sions to optimize or change treatment in both clinically
active RA patients and in patients in remission/LDA.
The aim of the present paper is to explore if synovial
hypertrophy in joints without Doppler activity is sensi-
tive to change, as compared with synovial hypertrophy
in joints with Doppler activity, when initiating or switch-
ing treatment with bDMARDs in patients with RA. Fur-
thermore, the relationship between the presence of
synovial hypertrophy with and without Doppler activity
and clinical evaluation of disease activity is investigated.
Methods
The study cohort comprised of patients with RA fulfilling
the American College of Rheumatology (ACR) 1987 cri-
teria [21] initiating or switching bDMARD treatment in
the period from January 2010 to June 2013 (Anzctr.org.au
identifier, ACTRN12610000284066). Clinical evaluation
(number of tender and swollen joints (= 28), patient and
assessor global visual analogue scale (VAS), C-reactive
protein (CRP), and US examinations of 36 joints) were
performed at baseline, and at 3 and 6 months. Two
trained study nurses with longstanding experience in
evaluating tender and swollen joints performed the clinical
evaluations blinded to the US findings. Disease Activity
Score 28-joint count (DAS28)-CRP was calculated for
each visit.
US examinations (blinded for the results of the clinical
assessments) were performed by the same experienced so-
nographer (HBH) throughout the study using a Siemens
Antares, Excellence version (Siemens Medical Solutions,
CA, USA) equipped with a 5–13 MHz linear probe. Power
Doppler settings were optimized for inflammatory flow
with pulse repetition frequency 391 Hz, Doppler fre-
quency 7.3 MHz, and gain just below the level of noise ac-
cording to guidelines [22]. The same ultrasound machine
with the same settings was used throughout the study and
no software upgrade was done.
At each visit, US examination for signs of synovitis
was performed for the following 18 joints bilaterally:
metacarpophalangeal joints 1–5, proximal interphalan-
geal joints 2–3, wrist (scoring radiocarpal, intercarpal,
and radioulnar joints separately), elbow, knee, talocrural,
and metatarsophalangeal joints 1–5. Each joint at each
visit was scored semiquantitatively from 0–3 for GS and
power Doppler (PD) according to the US atlas of Ham-
mer et al. [8]. Joints with recent surgery, prosthesis, or
overlying skin infections were not examined at time of
inclusion or during follow-up. The performing sonogra-
pher has previously demonstrated a high intra-observer
reliability (weighted kappa 0.83 [8]) for the included
joints using this atlas [8] for scoring.
The study was approved by the Regional Committee
for Medical and Health Research Ethics, South-East
Norway, and all patients gave written consent according
to the Declaration of Helsinki.
A post-hoc analysis was carried out on those patients
from the original cohort [23] fulfilling all follow-up
visits. Only joints with follow-up at all time points were
included in the analysis.
The primary endpoint of the study was to assess the
relative frequency of a synovial hypertrophy score
change ≥ 1 in joints without Doppler activity versus
joints with Doppler activity in all joints having a baseline
synovial hypertrophy of grade 1 or above. The changes
were assessed from baseline to 3-month follow-up and
baseline to 6-month follow-up. The secondary endpoint
was the correlation between the change in mean synovial
hypertrophy score in joints without Doppler activity and
the change in mean synovial hypertrophy score in joints
with Doppler activity in joints with baseline synovial
hypertrophy of grade 1 or above. This was assessed from
baseline to 3-month follow-up and baseline to 6-month
follow-up. The tertiary outcome was the association be-
tween the mean grade of synovial hypertrophy in joints
and the presence/absence of clinical joint tenderness
and presence/absence of clinical joint swelling in joints
as follows: 1) at 3 months in joints with baseline
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Doppler activity; 2) at 6 months in joints with baseline
Doppler activity; 3) at 3 months in joints without base-
line Doppler activity; and 4) at 6 months in joints with-
out baseline Doppler activity. Finally, we assessed the
correlation between changes in mean synovial hyper-
trophy in Doppler-negative joints, Doppler-positive
joints, and changes in DAS28-CRP from baseline to
3-month follow-up and baseline to 6-month follow-up.
Statistics
R statistical software version 3.3.2 was used for analyses.
To assess differences in the tendency of synovial hyper-
trophy to decrease between Doppler-positive versus
Doppler-negative joints, the corresponding odds ratio
between these two groups was estimated. This was per-
formed using a logistic mixed-effects model, where the
dependent variable was decrease in synovial hypertrophy
from baseline ≥ 1 point, coded as a binary variable equal
to 1 if a decrease was observed (for a given joint at a
given time point) and 0 otherwise. The independent
variable was Doppler status of the joint at baseline (0 if
Doppler = 0, 1 if Doppler > 0), further adjusting for both
baseline synovial hypertrophy level of each joint as well
as the observation time (treated as a categorical vari-
able). To account for dependencies between observa-
tions from the same patient, as well as from the same
joint, random intercepts for both terms were included in
the model. Only joints with synovial hypertrophy at
baseline were included in the analysis, and the model
was fit using data at both 3 and 6 months. The differ-
ence in mean grade synovial hypertrophy between ten-
der and non-tender joints was evaluated using a
bootstrap test. The same was performed for joint swell-
ing. Correlation between change in mean synovial hyper-
trophy across joints and change in DAS28-CRP was
calculated using Spearman’s correlation.
Results
Of the original cohort of 212 patients [23], 151 com-
pleted both baseline and 3- and 6-month follow-up.
Baseline demographics for the included patients are
listed in Table 1.
In total, 5225 joints were evaluated at baseline and, of
these, 1191 joints had synovial hypertrophy without Dop-
pler activity but only 1172 had follow-up at both 3 and
6 months. At baseline, 1154 had synovial hypertrophy
with Doppler activity, but only 1122 had follow-up at 3
and 6 months. The reasons that joints were unavailable
for US examination at 3 and/or 6 months included recent
surgery, including prosthesis surgery, joint trauma, or
overlying skin infections.
Joints with synovial hypertrophy without Doppler activity
had overall lower grades of synovial hypertrophy (1.3 ± 0.3
(mean ± standard deviation (SD)) than joints with synovial
hypertrophy with Doppler activity (2.1 ± 0.5) at baseline. In
general, joints with lower levels of synovial hypertrophy
had lower tendency towards change (Table 2).
Improvement in synovial hypertrophy during treatment
The overall frequency of change in synovial hypertrophy
in joints without Doppler activity and joints with Dop-
pler activity was similar at both 3 months (0.54 and 0.53,
respectively) and 6 months (0.56 and 0.60, respectively)
(Table 2). However, when adjusting for the baseline
grade of synovial hypertrophy, the change was signifi-
cantly different between joints with and without Doppler
activity. The adjusted odds ratios were 0.35 at 3 months
and 0.39 at 6 months, showing that joints with synovial
hypertrophy with Doppler activity were significantly less
likely to change than joints with synovial hypertrophy
without Doppler activity for all grades (3 months: p <
0.0001; 6 months p = 0.0003).
The mean ± SD synovial hypertrophy in joints without
Doppler activity at both 3 and 6 months was 1.3 ± 0.3
with a change from baseline of −0.5 ± 0.4 and −0.6 ± 0.4,
respectively. In joints with synovial hypertrophy with
Doppler activity, the synovial hypertrophy score at both
3 and 6 months was 2.1 ± 0.5 with a change at 3 months
of −0.7 ± 0.6 and at 6 months of −0.8 ± 0.6. The change
in mean synovial hypertrophy score in joints with and
without Doppler activity correlated significantly at both
Table 1 Demographic data for the 151 patients
Patients 82.8% women
Age (years) 51.4 ± 13.2
Anti-CCP 80.1% positive
Rheumatoid factor 75.2% positive
Disease duration (years) 9.9 ± 7.9
Number of swollen joints 6.49 ± 5.5
Number of tender joints 5.98 ± 6.4
bDMARDs initiated in the study
cohort
Infliximab (n = 19), etanercept
(n = 59), adalimumab (n = 8),
certolizumab (n = 12), golimumab
(n = 8), rituximab (n = 30), tocilizumab
(n = 8), and abatacept (n = 5); 8% of
the patients were biologic naive
Prednisolone treated 50.7%
Prednisolone dose 7.8 ± 4.68 mg
DAS28-CRP score 4.14 ± 1.32)
Total number of joints examined,
n
5225
Joints with SH and no Doppler
at baseline, n (%)
1191 (23%)
Joints with SH and Doppler at
baseline, n (%)
1151 (22%)
Values are shown as mean ± standard deviation unless otherwise indicated
bDMARD biological disease-modifying antirheumatic drug, CCP cyclic
citrullinated peptide, DAS28-CRP Disease Activity Score 28-joint count C-
reactive peptide, SH synovial hypertrophy
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3 and 6 months (r = 0.37, p < 0.0001, and r = 0.34, p <
0.0001, respectively).
Of the joints with synovial hypertrophy without Doppler
activity included in the analysis, 43% had achieved a synovial
hypertrophy score of 0 at 3 months and 45% at 6 months
while, for the joints with synovial hypertrophy with Doppler
activity, this was found in 20% and 24% at 3 and 6 months,
respectively. The frequency of different synovial hypertrophy
grades at different time points are shown in Table 3.
The mean synovial hypertrophy grade in different joint
groups were comparable (mean 1.23, range 1.15–1.53, at
baseline in joints with synovial hypertrophy without
Doppler activity). All joint groups showed an improve-
ment in synovial hypertrophy at both 3 and 6 months
compared with baseline (data not shown).
Association between mean grade of synovial hypertrophy
and clinical evaluation
Joint swelling
When evaluating the joints with synovial hypertrophy with-
out Doppler activity there was a significantly higher grade
of synovial hypertrophy in joints with clinical joint swelling
compared with joints without clinical joint swelling at all
time points (p < 0.0001). At baseline, the mean grade of
synovial hypertrophy was 0.81 in clinical swollen joints as
opposed to 0.22 in non-swollen joints; at 3 months it was
0.92 versus 0.19, and at 6 months 1.07 versus 0.20. Similar
findings were seen in the joints with synovial hypertrophy
with Doppler activity but with higher mean synovial
hypertrophy score at all time points (2.56 in swollen versus
2.12 in non-swollen joints at baseline, 2.49 versus 1.95 at
3 months, and 2.53 versus 1.86 at 6 months).
Joint tenderness
When evaluating the joints with synovial hypertrophy
without Doppler activity, there was a significant differ-
ence in mean synovial hypertrophy score in clinically
tender joints compared with non-tender joints at all
time points (p < 0.0001). At baseline the mean synovial
hypertrophy score was 0.50 in clinically tender joints as
opposed to 0.24 in non-tender joints; at 3 months the
results were 0.44 versus 0.22, and at 6 months 0.48 ver-
sus 0.23, respectively. However, in joints with synovial
hypertrophy with Doppler activity there was no statisti-
cally significant difference in mean synovial hypertrophy
score between clinically tender and non-tender joints at
any time point (2.45 in tender versus 2.45 in non-tender
joints at baseline, 2.29 versus 2.31 at 3 months, and 2.38
versus 1.33 at 6 months).
Correlation between synovial hypertrophy and DAS28-CRP
remission
There was a weak but statistically significant correlation
between change in the mean synovial hypertrophy score
across all joints and the change in DAS28-CRP for joints
with synovial hypertrophy with as well as without Dop-
pler activity. The correlation coefficient for joints with
synovial hypertrophy without Doppler activity was 0.28
(p = 0.001) at 3 months and 0.17 (p = 0.03) at 6 months.
For joints with synovial hypertrophy with Doppler activ-
ity, the correlation coefficient was 0.23 (p = 0.007) at
3 months and 0.34 (p = 0.001) at 6 months.
Discussion
The present study reveals that joints with synovial
hypertrophy without Doppler activity are sensitive to
Table 2 Improvement in synovial hypertrophy (SH) in joints with and without Doppler activity
Time Grades Joints with SH without Doppler activity Joints with SH with Doppler activity Adjusted
odds ratio
p value
Number of joints Frequency of
improvement
Number of joints Frequency of
improvementBaseline With improvement Baseline With improvement
3 months All grades 1172 637 0.54 1122 594 0.53 0.35 < 0.0001
Grade 1 863 441 0.51 169 58 0.35
Grade 2 269 164 0.61 494 271 0.55
Grade 3 40 32 0.80 459 265 0.58
6 months All grades 1172 657 0.56 1122 669 0.60 0.39 0.0003
Grade 1 863 457 0.53 169 58 0.34
Grade 2 269 167 0.62 494 312 0.63
Grade 3 40 33 0.82 459 299 0.65
The table shows the frequency of improvement in joints at 3 and 6 months for all grades overall and separately for each grade
The relative frequency of a SH score decrease ≥ 1 were analyzed using a generalized linear mixed model adjusting for baseline SH score using a separate
coefficient per time point
Table 3 The frequency of different synovial hypertrophy (SH)
grades at different time points
Time SH grade 0 SH grade 1 SH grade 2 SH grade 3
Baseline 53.9% 19.1% 14.2% 9.3%
3 months 61.1% 19% 11% 5%
6 months 61.6% 19.1% 10% 4.3%
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change during bDMARD treatment and, when taking
into account the baseline score of the synovial hyper-
trophy, joints with synovial hypertrophy without Doppler
activity have a higher tendency towards change than
joints with synovial hypertrophy with Doppler activity,
independent of the grade.
Even though the treatment effect is evaluated by both
GS and Doppler, the main focus is often on the changes
in Doppler activity since the Doppler activity is believed
to reflect the inflammatory component of the disease
[11, 12, 14, 16, 18]. Although the two components in
synovitis (i.e., synovial hypertrophy and hyperemia) are
likely to change in parallel when treatment is initiated
[10, 24, 25], there has been a lack of evidence of the abil-
ity for joints with initial synovial hypertrophy without
signs of hyperemia to change per se during treatment. In
2013, Witt et al. [18] showed that synovial hypertrophy
grade 1 in cohorts of both early and late RA patients
was less likely to respond to treatment and, furthermore,
grade 1 was also found in healthy controls. These grade
1 findings were not associated with swelling or tender-
ness in either RA patients or healthy controls. Padovano
et al. reported similar frequent findings of grade 1 syn-
ovial hypertrophy among healthy controls [26]. In the
current study, we have demonstrated that, in RA pa-
tients, synovial hypertrophy both with and without Dop-
pler activity has the ability to improve when initiating
effective treatment, even grade 1 synovial hypertrophy.
Similar results have been seen for tenosynovitis, where
grade 1 tenosynovitis without Doppler improves during
treatment [27]. The US changes were also compared
with changes in DAS28-CRP (i.e., to clinical assessment
of treatment response). A weak but significant correl-
ation was found between changes in DAS28-CRP and
changes in mean synovial hypertrophy score for both
joints with and without Doppler activity, indicating that
the improvements in the joints are in line with the over-
all disease improvement during treatment. Furthermore,
in the current study, the mean grade of synovial hyper-
trophy was higher in joints with than without Doppler
activity, both in tender and swollen joints, supporting
that both measures reflect aspects of disease activity.
The present study shows that synovial hypertrophy is sus-
ceptible to change during treatment but does not indicate
which of the two components is the most important. In a re-
cent publication from the Outcome Measures in Rheumatol-
ogy (OMERACT) US group [9, 28], a consensus-based
scoring system for synovitis in RA patients has been devel-
oped taking both components of the synovitis complex into
account in a combined score. The relevance of including the
GS synovial hypertrophy in this scoring is further substanti-
ated by the findings in the present study.
The impact of Doppler sensitivity on scoring has pre-
viously been investigated and it has been shown that
suboptimal settings and suboptimal equipment may re-
sult in lack of Doppler activity in inflamed joints [29]. In
the present study, high-end US equipment was used to
make sure that the detected joints with synovial hyper-
trophy but no Doppler activity truly reflected a lack of
hyperemia in the joints.
Conclusion
Our study shows that joints with synovial hypertrophy
without Doppler activity improve during bDMARD
treatment, demonstrating that synovial hypertrophy
without Doppler activity is a sign of active disease. These
findings indicate that joints with synovial hypertrophy
without Doppler activity should be taken into account
when assessing disease activity by ultrasound.
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